Cellectar Biosciences, Inc. (CLRB)
CLRB Stock Price Chart
Explore Cellectar Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CLRB price movements and trends.
CLRB Company Profile
Discover essential business fundamentals and corporate details for Cellectar Biosciences, Inc. (CLRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Nov 2005
Employees
11.00
Website
https://www.cellectar.comCEO
James V. Caruso
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB Financial Timeline
Browse a chronological timeline of Cellectar Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 17 Nov 2025
EPS estimate is -$1.91.
Earnings released on 14 Aug 2025
EPS came in at -$3.39 surpassing the estimated -$3.60 by +5.83%.
Stock split effective on 24 Jun 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$3.90 surpassing the estimated -$5.11 by +23.68%.
Earnings released on 13 Mar 2025
EPS came in at -$0.01 surpassing the estimated -$0.38 by +97.37%.
Earnings released on 29 Oct 2024
EPS came in at -$0.51 falling short of the estimated -$0.37 by -37.84%.
Earnings released on 13 Aug 2024
EPS came in at -$0.73 falling short of the estimated -$0.23 by -217.39%.
Earnings released on 14 May 2024
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%.
Earnings released on 27 Mar 2024
EPS came in at -$0.66 falling short of the estimated -$0.59 by -11.86%, while revenue for the quarter reached $330.37K .
Earnings released on 13 Nov 2023
EPS came in at -$0.82 falling short of the estimated -$0.44 by -86.36%.
Earnings released on 14 Aug 2023
EPS came in at -$0.73 falling short of the estimated -$0.69 by -5.80%.
Earnings released on 4 May 2023
EPS came in at -$0.76 falling short of the estimated -$0.75 by -1.33%.
Earnings released on 9 Mar 2023
EPS came in at -$0.55 surpassing the estimated -$0.83 by +33.73%.
Earnings released on 3 Nov 2022
EPS came in at -$1.28 falling short of the estimated -$1.21 by -5.79%.
Earnings released on 5 Aug 2022
EPS came in at -$1.22 falling short of the estimated -$1.08 by -12.96%.
Stock split effective on 22 Jul 2022
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2022
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%.
Earnings released on 21 Mar 2022
EPS came in at -$1.00 matching the estimated -$1.00.
Earnings released on 8 Nov 2021
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%.
Earnings released on 9 Aug 2021
EPS came in at -$1.10 matching the estimated -$1.10.
Earnings released on 10 May 2021
EPS came in at -$1.30 falling short of the estimated -$0.90 by -44.44%.
Earnings released on 2 Mar 2021
EPS came in at -$0.70 surpassing the estimated -$1.50 by +53.33%.
Earnings released on 9 Nov 2020
EPS came in at -$1.50 matching the estimated -$1.50.
CLRB Stock Performance
Access detailed CLRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.